News &
Media
-
Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
View MoreNeurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
-
Neurotech Releases ASD Medical Cannabis Study Results
View MoreAustralia’s Neurotech International Limited (ASX: NTI) has announced what it says are successful outcomes of its medical cannabis formulation on key behavioural issues impacting kids with autism.
-
Neurotech International (ASX:NTI) Webinar – Breakthrough results with NTI164 in paediatric ASD
View More -
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
View MoreNeurotech has released promising results from a world-first study of a medicinal cannabis product which could be a game changer in treating children with autism.
-
Neurotech study finds children with autism benefit from cannabis product
View MoreNeurotech International (ASX:NTI) has today announced its patent NTI164 product has been proven to reduce ASD symptoms in children and teenagers.
-
Neurotech International announces breakthrough results from autism study
View MoreNeurotech International has announced breakthrough results from a clinical trial of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study
View MoreNeurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).
-
Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
View MoreThe cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).